OBJECTIVE: To examine aggression, antisocial behavior, and substance abuse in young adult survivors of pediatric cancer (PCS) relative to case control peers (CC). METHODS: We obtained self-reports of current aggression, antisocial behavior, and lifetime substance use from 26 PCS (time off-treatment, M: = 56 months) and 26 CC using the Antisocial Behavior Checklist and the Drinking and Drug History. A report of current aggression and antisocial behavior also was obtained from primary caregivers using the Child Behavior Checklist. RESULTS: PCS self-reported significantly less illegal drug use and experimentation than CC. No significant differences emerged between groups for use of alcohol and tobacco nor for aggression and antisocial behavior. CONCLUSIONS: PCS are functioning as well as, or better than, CC in terms of aggression, antisocial behavior, and substance abuse. However, given the compromised health status of survivors, efforts should focus on further reduction of drug-related risk behaviors that may amplify organ damage or increase risk for further malignancies in this population.
OBJECTIVE: To examine aggression, antisocial behavior, and substance abuse in young adult survivors of pediatric cancer (PCS) relative to case control peers (CC). METHODS: We obtained self-reports of current aggression, antisocial behavior, and lifetime substance use from 26 PCS (time off-treatment, M: = 56 months) and 26 CC using the Antisocial Behavior Checklist and the Drinking and Drug History. A report of current aggression and antisocial behavior also was obtained from primary caregivers using the Child Behavior Checklist. RESULTS: PCS self-reported significantly less illegal drug use and experimentation than CC. No significant differences emerged between groups for use of alcohol and tobacco nor for aggression and antisocial behavior. CONCLUSIONS: PCS are functioning as well as, or better than, CC in terms of aggression, antisocial behavior, and substance abuse. However, given the compromised health status of survivors, efforts should focus on further reduction of drug-related risk behaviors that may amplify organ damage or increase risk for further malignancies in this population.
Authors: Lisa S Kahalley; Vida L Tyc; Stephanie J Wilson; Jenna Nelms; Melissa M Hudson; Shengjie Wu; Xiaoping Xiong; Pamela S Hinds Journal: J Cancer Surviv Date: 2010-10-05 Impact factor: 4.442
Authors: Taghrid Asfar; Noella A Dietz; Kristopher L Arheart; Stacey L Tannenbaum; Laura A McClure; Lora E Fleming; David J Lee Journal: J Cancer Surviv Date: 2015-06-02 Impact factor: 4.442
Authors: Leslee Throckmorton-Belzer; Vida L Tyc; Leslie A Robinson; James L Klosky; Shelly Lensing; Andrea K Booth Journal: Child Health Care Date: 2009-10-01
Authors: Todd M Gibson; Wei Liu; Gregory T Armstrong; Deo Kumar Srivastava; Melissa M Hudson; Wendy M Leisenring; Ann C Mertens; Robert C Klesges; Kevin C Oeffinger; Paul C Nathan; Leslie L Robison Journal: Cancer Date: 2015-08-19 Impact factor: 6.860
Authors: P J Hollen; V L Tyc; S V Shannon; S F Donnangelo; W L Hobbie; M M Hudson; M C O'Laughlen; M E Smolkin; G R Petroni Journal: J Cancer Surviv Date: 2013-05-28 Impact factor: 4.442
Authors: James L Klosky; Darlene K Cash; Joanna Buscemi; Shelly Lensing; Danette M Garces-Webb; Wenyan Zhao; Sally Wiard; Melissa M Hudson Journal: J Cancer Surviv Date: 2008-09-12 Impact factor: 4.442
Authors: Caitlin B Murray; Jaclyn M Lennon; Katie A Devine; Grayson N Holmbeck; Kimberly Klages; Lauren M Potthoff Journal: Health Psychol Date: 2014-02-03 Impact factor: 4.267
Authors: E Anne Lown; Robert Goldsby; Ann C Mertens; Thomas Greenfield; Jason Bond; John Whitton; Rachael Korcha; Leslie L Robison; Lonnie K Zeltzer Journal: Addiction Date: 2008-07 Impact factor: 6.526